Target Price | $9.57 |
Price | $7.26 |
Potential |
31.84%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Aurinia Pharmaceuticals Inc. 2025 .
The average Aurinia Pharmaceuticals Inc. target price is $9.57.
This is
31.84%
register free of charge
$13.00
79.06%
register free of charge
$6.00
17.36%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend Aurinia Pharmaceuticals Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Aurinia Pharmaceuticals Inc. stock has an average upside potential 2025 of
31.84%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 175.51 | 231.50 |
30.95% | 31.90% | |
EBITDA Margin | -40.84% | 16.85% |
50.37% | 141.26% | |
Net Margin | -43.99% | 0.31% |
45.74% | 100.70% |
7 Analysts have issued a sales forecast Aurinia Pharmaceuticals Inc. 2024 . The average Aurinia Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Aurinia Pharmaceuticals Inc. 2024 . The average Aurinia Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Aurinia Pharmaceuticals Inc. Analysts have issued a net profit forecast 2024. The average Aurinia Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.54 | 0.01 |
28.95% | 101.85% | |
P/E | 1,452.00 | |
EV/Sales | 3.43 |
2 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast for earnings per share. The average Aurinia Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Aurinia Pharmaceuticals Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Aurinia Pharmaceuticals Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.